Guardant Health, Inc.

Listed Company

GHCIK 0001576280NasdaqLarge AcceleratedServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$982.02M

Net Income

$-416.28M

Total Assets

$2.01B

Equity

$-99.31M

Shares Out

131.17M

Op. Cash Flow

$-184.76M

Business

Guardant Health, Inc. is a precision oncology company that develops and commercializes blood- and tissue-based molecular diagnostic tests and real-world data solutions to inform cancer detection, monitoring and therapy selection. Its main products include Guardant360 CDx and LDT, Guardant Reveal, Guardant360 Response, Guardant360 TissueNext, the Shield screening test, GuardantINFINITY, GuardantOMNI, the GuardantINFORM data platform and GuardantConnect trial-matching services. The company operates clinical diagnostics, biopharmaceutical services and data analytics segments. It distributes tests and services to clinicians, cancer centers and biopharmaceutical customers in the U.S. and internationally via direct sales, partnerships, laboratory collaborations and distributors.

Summary from filing dated 2025-02-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	982	739	564	450	374
Cost of revenue	349	290	227	—	—
Research and development expense	364	348	367	374	263
Sales and marketing expense	495	365	295	300	192
General and administrative expense	211	180	156	164	207
Other operating expense	0	0	83	0	0
Total costs and operating expenses	1,419	1,183	1,129	994	785
Loss from operations	−437	−444	−565	−544	−411
Interest income	34	54	35	6	4
Interest expense	−4	−3	−3	−3	—
Other income (expense), net	−10	−43	53	−13	25
Loss before (benefit from) provision for income taxes	−418	−435	−479	−653	−384
(Benefit from) provision for income taxes	−1	1	685,000	1	300,000
Net loss	−416	−436	−479	−655	—
Net loss per share, basic (in usd per share)	−3.32	−3.56	−4.28	−6.41	−4
Net loss per share, diluted (in usd per share)	−3.32	−3.56	−4.28	−6.41	−4
Weighted-average shares used in computing net loss per share, basic (in shares)	125	123	112	102	101
Weighted-average shares used in computing net loss per share, diluted (in shares)	125	123	112	102	101

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	378	526	1,134	142	492
Short-term marketable debt securities	823	314	35	870	—
Accounts receivable, net	138	110	89	97	98
Inventory, net	86	71	62	52	31
Prepaid expenses and other current assets, net	41	34	28	32	53
Total current assets	1,466	1,055	1,347	1,192	1,114
Restricted cash	111	104	150,000	0	—
Property and equipment, net	146	137	145	168	124
Right-of-use assets, net	159	142	158	174	189
Intangible assets, net	26	7	9	12	14
Goodwill	77	3	3	3	3
Other assets, net	28	37	124	61	61
Total Assets	2,014	1,486	1,786	1,610	2,204
Accounts payable	54	39	52	—	18
Accrued compensation	120	83	73	—	—
Accrued expenses	78	68	—	—	45
Deferred revenue	51	35	18	17	—
Total current liabilities	303	226	206	193	195
Convertible senior notes, net	1,504	1,143	1,140	1,137	1,135
Long-term operating lease liabilities	178	164	186	210	226
Other long-term liabilities	128	93	96	9	4
Total Liabilities	2,113	1,625	1,628	1,550	1,559
Commitments and contingencies	—	—	—	—	—
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2025 and 2024; 130,635,301 and 123,994,006 shares issued and outstanding as of December 31, 2025 and 2024, respectively	1,000	1,000	1,000	1,000	1,000
Additional paid-in capital	2,900	2,444	2,304	1,742	1,658
Accumulated other comprehensive loss	−5	−5	−4	−20	−5
Accumulated deficit	−2,995	−2,578	−2,142	−1,662	−1,008
Total Stockholders Deficit	−99	−140	159	60	645
Total Liabilities and Stockholders Deficit	2,014	1,486	1,786	1,610	2,204

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	40	42	43	36	22
Operating lease costs	34	31	30	29	25
Gain on extinguishment of convertible notes	−14	0	0	—	—
Stock-based compensation	166	140	91	95	151
Interest income received on marketable debt securities	8	0	0	—	—
Amortization of discount on marketable debt securities	−6	−7	−14	5	13
Unrealized and realized losses (gains) on marketable equity securities	0	44	−80	8	—
Impairment of non-marketable equity securities and other related assets	19	0	29	5	0
Other	−294,000	6	2	21,000	47,000
Accounts receivable, net	−28	−21	8	375,000	−44
Inventory, net	−15	−9	−10	−21	−8
Prepaid expenses and other current assets, net	−6	−8	−4	20	−36
Other assets, net	212,000	−2	1	12	−4
Accounts payable and accrued liabilities	53	−3	5	60	35
Other legal liabilities	0	0	83	0	—
Operating lease liabilities	−38	−36	−31	−20	14
Deferred revenue	19	19	2	10	3
Net cash used in operating activities	−185	−240	−325	−309	−209
Purchases of marketable debt securities	−818	−307	−630	−304	−901
Maturities of marketable debt securities	307	35	1,495	555	952
Sales of marketable equity securities and other related assets	0	54	2	0	—
Purchases of non-marketable equity securities and other related assets	−9	−8	−6	−24	−39
Purchases of property and equipment	−48	−35	−20	−77	−75
Acquisition of business, net of cash acquired	−59	0	0	—	0
Net cash (used in) provided by investing activities	−627	−261	840	150	−63
Proceeds from issuance of common stock under employee stock purchase plan	14	12	10	9	10
Proceeds from issuance of common stock upon exercise of stock options	19	3	405,000	3	8
Employee taxes paid related to net share settlement of restricted stock units	−31	−16	−11	−8	−84
Repurchase of treasury stock	−45	0	0	—	—
Proceeds from reissuance of treasury stock	88	0	0	—	—
Proceeds from equity offerings	257	0	493	0	0
Payment of equity offering costs	−18	0	−21	0	0
Proceeds from borrowings on convertible senior notes	403	0	0	0	0
Payment of debt issuance costs	−25	0	0	0	−784,000
Proceeds from unwinding of convertible note hedges	5	0	0	—	—
Other	4	−153,000	6	−1	−930,000
Net cash provided by (used in) financing activities	671	−996,000	477	−189	−67
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	491,000	−2	−911,000	−2	−2
Net (decrease) increase in cash, cash equivalents and restricted cash	−140	−504	992	−350	−341
Cash paid for interest	4	0	0	—	0
Cash paid for income taxes	869,000	1	2	1	393,000
Operating lease liabilities arising from obtaining right-of-use assets	41	8	5	4	171
Purchases of property and equipment included in accounts payable and accrued liabilities	4	4	5	8	9

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro